What is Agentix Corp?
, a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.52M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.